NCT00136331View on ClinicalTrials.gov

Study of a Pandemic Influenza Vaccine

PHASE1CompletedINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

October 31, 2005

Study Completion Date

November 30, 2006

Conditions
Influenza
Interventions
BIOLOGICAL

Pandemic influenza vaccine

Trial Locations (2)

3052

Murdoch Childrens Research Institute, Melbourne

5000

CMAX, a division of IDT Australia, Adelaide

All Listed Sponsors
lead

Seqirus

INDUSTRY

NCT00136331 - Study of a Pandemic Influenza Vaccine | Biotech Hunter | Biotech Hunter